News

Via its supply chain network, drug wholesaler has helped deliver more than 75 million vaccines

Marken/UPS, LifeScience Logistics and Packaging Technology Group are among the latest contenders

Company officials predict 500 million vaccine doses per year to be produced via the center, which will offer fill-finish, packaging services

Previous merger earns clinical research company $235 million as it looks to advance patient enrollment

Company officials believe new facility will help meet ongoing demand for temperature-controlled packaging

Using AI and data engineering insight, purchase offers customers potential to shorten clinical trials and accelerate time to commercialization

Pace of production plays a major role, says study

Manufacturing facility to provide 1.5 million square feet of bioproduction technologies

Will feature laboratories intended for R&D

Can monitor vials for temperature breaches at any point in cold chain, developer says

Collaboration centers around providing assistance to multiple links in the clinical trial chain, from participants to providers

Development of additional 29,000 square feet addresses med tech company’s internal production capabilities

Recent FDA actions may finally usher in access boost to follow-on biologics in the US

R&D partnership with VaxEquity outlines plan to use saRNA as a go-to therapeutic

Polish facility will be based on GDP and ISO practices

Financial commitment expected to expand the development and commercialization pipeline for new medicines

UK location offers close proximity to London Heathrow Airport

Side effects were consistent with 16-25 age group

Both Comirnaty, Spikevax jabs had previously been authorized for use under Interim Order

Deal is dependent on FDA approval of Phathom’s vonoprazan compound

Availability of space for new labs is a key selling point

Acquisition expected to help provide customers with a quicker clinical trial recruitment process

Five-year, nearly $90 million deal revolves around bulk drug substance formulation for Providence’s future shot

Expansion at German facility features new GMP manufacturing lines and a cleanroom, among other additions

Latest construction plan continues CDMO’s vision for biopharma expansion

FDA’s recommended guidance is for a system that ‘does not exist, cannot be built by 2023, and poses unacceptable security and compliance risks,’ says alliance

Biotech firm to file regulatory dossier with officials around the world

CDMO’s objective is to cater to various market segments in order to meet microbial bio-manufactured compound demand